KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Non-Current Assets (2017 - 2025)

Moderna (MRNA) has disclosed Other Non-Current Assets for 9 consecutive years, with $605.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 1.85% to $605.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $605.0 million through Dec 2025, up 1.85% year-over-year, with the annual reading at $605.0 million for FY2025, 1.85% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $605.0 million at Moderna, up from $530.0 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $1.3 billion in Q2 2023, with the low at $11.0 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $483.2 million, with a median of $556.0 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets surged 10650.0% in 2023, then crashed 50.31% in 2024.
  • Over 5 years, Other Non-Current Assets stood at $46.0 million in 2021, then surged by 2047.83% to $988.0 million in 2022, then decreased by 22.47% to $766.0 million in 2023, then fell by 22.45% to $594.0 million in 2024, then rose by 1.85% to $605.0 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $605.0 million, $530.0 million, and $546.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.